PRNewswire New Delhi [India] January 24 Attentiveai a leading AI-based SaaS startup today announced the successful close of its Series A2 funding round completing a 12M raise in Series A in two tranch ...

ServiceNow and Google Cloud today announced a major expansion of their partnership to maximize the value of generative AI across every layer of the enterprise technology stack. ServiceNow will bring ...

The vision for X Games' future under new CEO Jeremy Bloom includes sports betting, AI judging, fantasy sports and the debut ...

BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares.

Vertex specializes in corporate tax compliance software, targeting a $22 billion global TAM with a focus on enterprise and SMB markets. Recent acquisitions are masking Vertex's slower organic ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

The VERTEX 80 and the VERTEX 80v vacuum FT-IR spectrometers from Bruker are based on the actively aligned UltraScan ™ interferometer, which provides PEAK spectral resolution. The precise linear ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $440.68, marking a -0.72% move from the previous day. Vertex (VRTX) has received quite a bit of attention from Zacks.com ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...